Determinants of Virological Response to Antiretroviral Therapy: Socio-Economic Status Still Plays a Role in the Era of cART. Results from the ANRS-VESPA 2 Study,France

Abstract

Background

Disparities in combined antiretroviral therapy (cART) outcomes have been consistently reported among people living with HIV (PLWHIV). The present study aims at investigating the mechanisms underlying those disparities among PLWHIV in France.

Methods

We used data from the Vespa2 survey, a large national cross-sectional survey, representative of HIV-infected people followed at hospitals in 2011. Among participants diagnosed ≥1996, HIV treatment-naive at the time of cART initiation and on cART for at least 12 months, the frequency of sustained virological suppression (SVS; undetectable viral load [<50 copies/ml] for at least 6 months) at the time of the survey, was assessed and its social determinants were measured through logistic regression, accounting for clinical and biological determinants of response to cART.

Results

Among 1,246 participants, 77.7% had achieved SVS. SVS was less frequent among those unemployed (0.6 [range 0.3-1.0]) and those with the lowest level of education (0.4 [range 0.2-0.9]). The late presenters, diagnosed at a CD4⁺ T-cell count <200/mm³ (0.5 [range 0.3-0.9]) and the late starters, diagnosed at a CD4⁺ T-cell count >200 but initiating cART at CD4⁺ T-cell count <200 (0.3 [range 0.1-0.8]) were less likely than the ideal starters (≥350 CD4⁺ T-cells/mm³ at cART initiation) to achieve SVS, as were those who reported suboptimal adherence versus those reporting optimal adherence (0.4 [range 0.2-0.7]). In bivariate analyses, material deprivation, discrimination and a weak social network were also associated with a poorer treatment response.

Conclusions

Structural social factors remain strong determinants of treatment response and should be addressed in a broad approach of care, but wider political issues should also be investigated.

References

Nakagawa

, May

, Phillips

Life expectancy living with HIV: recent estimates and future implications.

Curr Opin Infect Dis 2013; 26: 17–25.

WHO. Global update on HIV treatment 2013: results, impact and opportunities. (Updated June 2013. Accessed 4 December 2015.) Available from http://www.who.int/hiv/pub/progressreports/update2013/en/.

Dray-Spira R, Spire B, Heard I, Lert F, VESPA Study Group.

Heterogeneous response to HAART across a diverse population of people living with HIV: results from the ANRS-EN12-VESPA Study.

AIDS 2007; 21 Suppl 1: S5–S12.

van den Berg

J.B.

, Hak

, Vervoort

S.C.J.M.

Increased risk of early virological failure in non-European HIV-1-infected patients in a Dutch cohort on highly active antiretroviral therapy.

HIV Med 2005; 6: 299–306.

Hodder

, Arasteh

, De Wet

Effect of gender and race on the week 48 findings in treatment-naive, HIV-1-infected patients enrolled in the randomized, Phase III trials ECHO and THRIVE.

HIV Med 2012; 13: 406–415.

Lourenço

, Colley

, Nosyk

High levels of heterogeneity in the HIV cascade of care across different population subgroups in British Columbia, Canada.

PLoS One 2014; 9: e115277.

Sumari-de Boer

I.M.

, Sprangers

M.A.G.

, Prins

J.M.

, Nieuwkerk

P.T.

HIV stigma and depressive symptoms are related to adherence and virological response to antiretroviral treatment among immigrant and indigenous HIV infected patients.

AIDS Behav 2012; 16: 1681–1689.

Althoff

K.N.

, Justice

A.C.

, Gange

S.J.

Virologic and immunologic response to HAART, by age and regimen class.

AIDS 2010; 24: 2469–2479.

Farías

A.A.

, Kremer

L.E.

, Allende

Determinants of immunological and virological responses to antiretroviral therapy amongst HIV-infected adults in central Argentina: negative influence of hepatitis C infection.

Trans R Soc Trop Med Hyg 2013; 107: 432–437.

10.

Syed

I.A.

, Sulaiman

S.A.S.

, Hassali

M.A.

, Syed

S.H.

, Shan

L.H.

, Lee

C.K.C.

Factors associated with poor CD4 and viral load outcomes in patients with HIV/AIDS.

J Med Virol 2016; 88: 790–797.

11.

Ballif

, Ledergerber

, Battegay

Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007.

PLoS One 2009; 4: e8275.

12.

Holkmann Olsen

, Mocroft

, Kirk

Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.

HIV Med 2007; 8: 96–104.

13.

Bosch

R.J.

, Bennett

, Collier

A.C.

, Zackin

, Benson

C.A.

Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy.

J Acquir Immune Defic Syndr 2007; 44: 268–277.

14.

Ironson

, O'Cleirigh

, Fletcher

M.A.

Psychosocial factors predict CD4 and viral load change in men and women with human immunodeficiency virus in the era of highly active antiretroviral treatment.

Psychosom Med 2005; 67: 1013–1021.

15.

Hanna

D.B.

, Buchacz

, Gebo

K.A.

Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001–2009.

Clin Infect Dis 2013; 56: 1174–1182.

16.

Westergaard

R.P.

, Hess

, Astemborski

, Mehta

S.H.

, Kirk

G.D.

Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users.

AIDS 2013; 27: 2559–2566.

17.

Monge

, Alejos

, Dronda

Inequalities in HIV disease management and progression in migrants from Latin America and sub-Saharan Africa living in Spain.

HIV Med2013; 14: 273–283.

18.

Burch

L.S.

, Smith

C.J.

, Phillips

A.N.

, Johnson

M.A.

, Lampe

F.C.

Socioeconomic status and response to antiretroviral therapy in high-income countries: a literature review.

AIDS 2016; 30: 1147–1162.

19.

Dray-Spira

, Spire

, Lert

le groupe VESPA-2. [General method of the ANRS-VESPA2 Study]. [General method of the ANRS-VESPA2 Study]. Bull Epidemiol Hebd 2013; 26-27: 321–324. French.

20.

WHO. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach: 2010 revision. (Accessed 4 December 2015.) Available from http://www.who.int/hiv/pub/arv/adult2010/en/.

21.

Kessler R, Andrews G, Mrokzek D, et al.

The World Health Organization Composite International Diagnostic Interview Short-Form (CIDI-SF).

Int J Methods Psychiatr Res 1998 7: 171–185.

22.

INSEE. National Institute of Statistics and Economic Studies. [Nomenclature of professional categories and professions (PCS)]. French. (Accessed 4 December 2015.) Available from http://www.insee.fr/fr/methodes/default.asp?page=nomenclatures/pcs2003/pcs2003.htm.

23.

Eurostat. European Union Statistics on Income and Living Conditions (EU-SILC). (Accessed 4 December 2015.) Available from http://ec.europa.eu/eurostat/web/microdata/european-union-statistics-on-income-and-living-conditions.

24.

Marsicano

, Dray-Spira

, Lert

Multiple discriminations experienced by people living with HIV in France: results from the ANRS-Vespa2 study.

AIDS Care 2014; 26 Suppl 1: S97–S106.

25.

Thompson

M.A.

, Aberg

J.A.

, Cahn

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.

JAMA 2010; 304: 321–333.

26.

Asboe

, Aitken

, Boffito

British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011.

HIV Med 2012; 13: 1–44.

27.

Dombrowski

J.C.

, Kitahata

M.M.

, Van Rompaey

S.E.

High levels of antiretroviral use and viral suppression among persons in HIV care in the United States, 2010.

J Acquir Immune Defic Syndr 2013; 63: 299–306.

28.

Skarbinski

, Rosenberg

, Paz-Bailey

Human immunodeficiency virus transmission at each step of the care continuum in the United States.

JAMA Intern Med 2015; 175: 588–596.

29.

Sobrino-Vegas

, Rodríguez-Urrego

, Berenguer

Educational gradient in HIV diagnosis delay, mortality, antiretroviral treatment initiation and response in a country with universal health care.

Antivir Ther 2012; 17: 1–8.

30.

Chakraborty

, Sen

P.K.

, Helms

R.W.

Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model.

AIDS 2001; 15: 621–627.

31.

Leserman

Role of depression, stress, and trauma in HIV disease progression.

Psychosom Med 2008; 70: 539–545.

32.

Gueler

, Schoeni-Affolter

, Moser

Neighbourhood socio-economic position, late presentation and outcomes in people living with HIV in Switzerland.

AIDS 2015; 29: 231–238.

33.

Desgrees-du-Lou

, Pannetier

, Ravalihasy

Is hardship during migration a determinant of HIV infection? Results from the ANRS PARCOURS study of sub-Saharan African Migrants in France.

AIDS 2016; 30: 645–656.

34.

International Labour Organization. The impact of employment on HIV treatment adherence. 2013. (Accessed 4 December 2015.) Available from http://www.ilo.org/aids/Publications/WCMS_230625/lang–en/index.htm.

35.

Howley

, Lartey

, Machan

J.T.

Highly active antiretroviral therapy and employment status in Accra, Ghana.

Ghana Med J 2010; 44: 144–149.

36.

Amico

K.R.

, Konkle-Parker

D.J.

, Cornman

D.H.

Reasons for ART non-adherence in the Deep South: adherence needs of a sample of HIV-positive patients in Mississippi.

AIDS Care 2007; 19: 1210–1218.

37.

Abgrall

Impact of socioeconomic status on virologic response (VR) to combination antiretroviral therapy (cART). ICAAC. 17 September 2015, San Diego, CA, USA. Poster H-1228.

38.

Katz

I.T.

, Leister

, Kacanek

Factors associated with lack of viral suppression at delivery among highly active antiretroviral therapy-naive women with HIV: a cohort study.

Ann Intern Med 2015; 162: 90–99.

39.

Burgoyne

R.W.

Exploring direction of causation between social support and clinical outcome for HIV-positive adults in the context of highly active antiretroviral therapy.

AIDS Care 2005; 17: 111–124.

40.

Falagas

M.E.

, Zarkadoulia

E.A.

, Pliatsika

P.A.

, Panos

Socioeconomic status (SES) as a determinant of adherence to treatment in HIV infected patients: a systematic review of the literature.

Retrovirology 2008; 5: 13.

41.

Bangsberg

D.R.

, Perry

, Charlebois

E.D.

Non-adherence to highly active antiretroviral therapy predicts progression to AIDS.

AIDS 2001; 15: 1181–1183.

42.

Gross

, Bilker

W.B.

, Friedman

H.M.

, Strom

B.L.

Effect of adherence to newly initiated antiretroviral therapy on plasma viral load.

AIDS 2001; 15: 2109–2117.

43.

Shuter

Forgiveness of non-adherence to HIV-1 antiretroviral therapy.

J Antimicrob Chemother 2008; 61: 769–773.

44.

Vitoria

, Ford

, Doherty

, Flexner

Simplification of antiretroviral therapy: a necessary step in the public health response to HIV/AIDS in resource-limited settings.

Antivir Ther 2014; 19 Suppl 3: 31–37.

45.

Collazos

, Asensi

, Carton

J.A.

, Ibarra

Grupo Español para el Estudio Multifactorial de la Adherencia. The influence of the patients’ educational levels on socioeconomic, clinical, immunological and virological endpoints. AIDS Care 2009; 21: 511–519.

46.

Zaragoza-Macias

, Cosco

, Nguyen

M.L.

, Del Rio

, Lennox

Predictors of success with highly active antiretroviral therapy in an antiretroviral-naive urban population.

AIDS Res Hum Retroviruses 2010; 26: 133–138.

47.

Weiss

, French

, Finkelstein

, Waters

, Mukherjee

, Agins

HIV-related knowledge and adherence to HAART.

AIDS Care 2003; 15: 673–679.

48.

Osborn

C.Y.

, Davis

T.C.

, Bailey

S.C.

, Wolf

M.S.

Health literacy in the context of HIV treatment: introducing the Brief Estimate of Health Knowledge and Action (BEHKA)-HIV version.

AIDS Behav 2010; 14: 181–188.

49.

Hicks

, Barragan

, Franco-Paredes

, Williams

M.V.

, del Rio

Health literacy is a predictor of HIV/AIDS knowledge.

Fam Med 2006; 38: 717–723.

50.

Palumbo

Discussing the effects of poor health literacy on patients facing HIV: a narrative literature review.

Int J Health Policy Manag 2015; 4: 417–430.

51.

Hartzell

J.D.

, Janke

I.E.

, Weintrob

A.C.

Impact of depression on HIV outcomes in the HAART era.

J Antimicrob Chemother 2008; 62: 246–255.

52.

WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. (Updated September 2015. Accessed 4 December 2015.) Available from http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/.

53.

Siegfried

, Uthman

O.A.

, Rutherford

G.W.

Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.

Cochrane Database Syst Rev 2010 3: CD008272.

54.

When To Start Consortium, Sterne

J.A.

, May

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.

Lancet 2009; 373: 1352–1363.

55.

Writing Committee for the CASCADE Collaboration.

Timing of HAART initiation and clinical outcomes among HIV-1 seroconverters.

Arch Intern Med 2011; 171: 1560–1569.

56.

Tabernilla

, Poveda

The START Trial: definitive evidence to treat all HIV-positive persons regardless of CD4 counts.

AIDS Rev 2015; 17: 187.

57.

Morlat

, Conseil National du Sida

A.N.R.S.

[Antiretroviral treatment, French guidelines 2013]. French. (Accessed 4 December 2015.) Available from http://social-sante.gouv.fr/IMG/pdf/Rapport_Morlat_2013_Mise_en_ligne.pdf.

58.

d'Almeida

K.W.

, Dray-Spira

, Aubrière

Frequency and correlates of late presentation for HIV infection in France: older adults are a risk group - results from the ANRS-VESPA2 Study, France.

AIDS Care 2014; 26 Suppl 1: S83–93.

59.

WHO. 90–90–90. An ambitious treatment target to help end the AIDS epidemic. 2014. (Accessed 4 December 2015.) Available from http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf.

60.

Cazein

, Le Strat

, Ramus

HIV testing in French medical laboratories, 2003-2014.

Bull Epidemiol Hebd 2015; 40-41: 769–771.

61.

Waters

, Nelson

Why do patients fail HIV therapy?

Int J Clin Pract 2007; 61: 983–990.

62.

Sledge

Structured treatment interruptions: after SMART.

BETA 2006; 18: 30–36.

63.

Jülg

, Goebel

F.D.

Treatment interruption in HIV therapy: a SMART strategy?

Infection 2006; 34: 186–188.

64.

Yazdanpanah

, Wolf

L.L.

, Anglaret

CD4⁺ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials.

Antivir Ther 2010; 15: 351–361.